Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Zimmer Biomet Shoulder Arthroplasty PMCF

Key facts

Who runs it
Zimmer Biomet
Where
Bloomington, Buffalo, Chicago, City of Saint Peters, Golden, Irvine, Jackson, Louisville, Murray, Philadelphia, Royal Oak, and St Louis, United StatesSee the 12 sitesAlso in 2 other countries, 5 sites
Trial code
Status
Recruiting
People taking part
584 people, planned
Started
28 Jul 2021
Expected to end
15 Aug 2033
Type of study
Interventional
Treatments tested
  • Alliance Glenoid
  • Identity Stem
Record updated
28 April 2026

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patient must be 20 years of age or older
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants
  • Patient is a candidate for shoulder arthroplasty due to one or more of the following:; Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis; Rheumatoid arthritis; Correction of functional deformity; Fractures of the proximal humerus, where other methods of treatment are deemed inadequate; Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate
  • Patient must be able and willing to complete the protocol required follow-up
  • Patient must be able and willing to sign the IRB/EC approved informed consent
  • Patient has grossly deficient rotator, (for reverse application); With severe arthropathy and/or; Previously failed shoulder joint replacement
  • Patient must have functional deltoid muscle (for reverse application)

Who cannot take part

  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant)
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable
  • Patient has a metabolic disorder that may impair bone formation
  • Patient is unwilling or unable to give consent or to comply with the follow-up program
  • Patient is known to be pregnant or breastfeeding
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device
  • Patient has osteomalacia
  • Patient has deficient rotator cuff
  • Patient presents with significant injury to the upper brachial plexus
  • Patient has paralysis of the axillary nerve
  • Patient has non-functional deltoid or external rotator muscles

Where in United States

Also in 2 other countries, 5 sites

  • TRIA Orthopaedic Center Research InstituteBloomington, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • University of BuffaloBuffalo, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Northwestern UniversityChicago, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Advance Bone and JointCity of Saint Peters, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Panorama Orthopaedic and Spine CenterGolden, United StatesContact: Paul Lee, PATaking people
  • Hoag Orthopedic InstituteIrvine, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Mississippi Sports Medicine and Orthopaedic Center PLLCJackson, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Norton Healthcare, Inc.Louisville, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Intermountain HealthMurray, United StatesContact: Maha Maleki, BSTaking people
  • Rothman InstitutePhiladelphia, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • William Beaumont HospitalRoyal Oak, United StatesContact: Cayla Lafollette, BSNo longer taking part
  • Washington UniversitySt Louis, United StatesContact: Cayla Lafollette, BSNo longer taking part

About the trial

What the trial wants to find out

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

The group in the trial

  • Zimmer Biomet Total Shoulder Arthroplasty SystemTreatment being tested

    Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.

    Treatment: Alliance Glenoid and Identity Stem

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study
Record updated
28 April 2026